114932-86-4

Usage

Uses

Used in Organic Synthesis:
Ethanone, 1-(tetrahydro-3-furanyl)(9CI) is used as a key intermediate in organic synthesis for the production of various chemical compounds. Its unique molecular structure allows for versatile reactions and the formation of a wide range of products.
Used in Pharmaceutical Research:
Ethanone, 1-(tetrahydro-3-furanyl)(9CI) is used as a starting material or building block in the development of new pharmaceutical compounds. Its unique properties and reactivity make it a valuable component in the synthesis of potential drug candidates.
Used in Flavor and Fragrance Industry:
Ethanone, 1-(tetrahydro-3-furanyl)(9CI) is used as a component in the production of various flavors and fragrances. Its unique chemical structure contributes to the creation of distinct scents and tastes, making it a valuable asset in the development of new products in this industry.

Upstream product

• 75-16-1 methylmagnesium bromide 
• 766539-67-7 N-methoxy-N-methyltetrahydrofuran-3-carboxamide 
• 89364-31-8 3-tetrahydrofuroic acid 

Relevant academic research and scientific papers

PURINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

COMPOUNDS USEFUL AS KINASE INHIBITORS

This invention relates to novel compounds. The compounds of the invention are tyrosine kinase inhibitors. Specifically, the compounds of the invention are useful as inhibitors of Bruton's tyrosine kinase (BTK).The invention also contemplates the use of the compounds for treating conditions treatable by the inhibition of Bruton's tyrosine kinase, for example cancer, lymphoma, leukemia and immunological diseases.

COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS

The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.